Results 191 to 200 of about 9,826,201 (402)

Aptamer Functionalized Hydrogel Dressings for Post‐Surgery Tumor Recurrence Inhibition and Tissue Reconstruction

open access: yesAdvanced Functional Materials, EarlyView.
Post‐surgical tumor therapy struggles with recurrence and inefficient healing. Anti‐tumor DNA aptamer functionalized gelatin hydrogels, Apt‐GelMA, simultaneously address both issues by suppressing tumor regrowth via targeted tumor cell inhibition and enhancing wound healing through improved cell adhesion and migration. Their biocompatibility, stability,
Tianyue Li   +11 more
wiley   +1 more source

THE CLINICAL PHARMACOLOGY OF SALMEFAMOL [PDF]

open access: bronze, 1974
M E Evans   +2 more
openalex   +1 more source

Clinical Pharmacology in the NHS [PDF]

open access: yesJournal of the Royal Society of Medicine, 1979
P N Bennett   +2 more
openaire   +4 more sources

Pharmacological and non-pharmacological treatments for the Neonatal Abstinence Syndrome (NAS). [PDF]

open access: yes, 2019
Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants develop after intrauterine maternal drug exposure. All infants with documented in utero opioid exposure, or a high pre-test probability of exposure should have ...
Kraft, W. K.   +2 more
core   +1 more source

Bioengineering Strategies for Treating Neointimal Hyperplasia in Peripheral Vasculature: Innovations and Challenges

open access: yesAdvanced Healthcare Materials, Volume 14, Issue 7, March 14, 2025.
This review highlights emerging bioengineering strategies for treating neointimal hyperplasia in the peripheral vasculature, focusing on approaches that promote re‐endothelialization, modulate smooth muscle cell phenotype, reduce inflammation, mitigate oxidative stress, and optimize biomechanical compliance.
Nikita Wilson John   +5 more
wiley   +1 more source

Reservoir‐Type Subcutaneous Implantable Devices Containing Porous Rate Controlling Membranes for Sustained Delivery of Risperidone

open access: yesAdvanced Healthcare Materials, EarlyView.
This study presents a novel implantable drug delivery systemwith a biodegradable poly(caprolactone) membrane and compressed drug core forsustained release. These implantable devices deliver risperidone in vitro for 170 days and in vivo for 49 days in rats, showing promise for chronic conditions like schizophrenia.
Linlin Li   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy